1118767-15-9

Basic information

• Product Name: 22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester
• CAS NO: 1118767-15-9
• Molecular Weight: 943.186
• Mol File: 1118767-15-9.mol
• Article Data: 5

Chemical Properties

• Density: 1.15±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester(CAS DataBase Reference)
• NIST Chemistry Reference: 22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester(1118767-15-9)
• EPA Substance Registry System: 22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester(1118767-15-9)

Safety Data

• Hazardous Substances Data: 1118767-15-9(Hazardous Substances Data)

Usage

General Description

22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester, due to its structural complexity, is likely part of the larger class of organic and bioorganic compounds known as polyethylene glycol (PEG) derivatives and protected amino acids. Its long-chain structure combined with several functional groups, including esters and carbonyl groups, suggests it may be used in the synthesis of peptides and other complex organic molecules. The N-hydroxysuccinimide ester functional group is commonly used in bioconjugation chemistry to attach molecules of interest to proteins or other substrates. The tert-butoxycarbonyl group is a protecting group used in peptide synthesis, implying this compound could feature in biochemical research and drug development. However, without specific application context or more details, it's challenging to provide a complete overview.

Upstream product

• 871-70-5 octadecanedioic acid 
• 45120-30-7 L-glutamic acid α-tert-butyl ester 
• 843666-34-2 octadecanedioic acid tert-butyl ester-2,5-dioxopyrrolidin-1-yl ester 
• 166108-71-0 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid 
• 84793-07-7 Fmoc-Glu-OtBu 
• 843666-40-0 1,18-octadecanedioic acid mono-tert-butyl ester 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 105832-38-0 O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 

Relevant articles and documents

Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320

Recently, the first basal oral insulin (OI338) was shown to provide similar treatment outcomes to insulin glargine in a phase 2a clinical trial. Here, we report the engineering of a novel class of basal oral insulin analogues of which OI338, 10, in this publication, was successfully tested in the phase 2a clinical trial. We found that the introduction of two insulin substitutions, A14E and B25H, was needed to provide increased stability toward proteolysis. Ultralong pharmacokinetic profiles were obtained by attaching an albumin-binding side chain derived from octadecanedioic (C18) or icosanedioic acid (C20) to the lysine in position B29. Crucial for obtaining the ultralong PK profile was also a significant reduction of insulin receptor affinity. Oral bioavailability in dogs indicated that C18-based analogues were superior to C20-based analogues. These studies led to the identification of the two clinical candidates OI338 and OI320 (10 and 24, respectively).

Novel GLP-1 Analogues

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Protease stabilized acylated insulin analogues

Novel acylated insulin analoges exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analoges contain B25H and A14E or A14H.